A Study in Healthy Subjects and Mild Asthmatics to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways
A Study in Healthy Subjects and Mild Asthmatics to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways
A study in healthy subjects and mild asthmatics to investigate Pharmacokinetics of AZD5423
 when administered in different ways.
Inclusion Criteria:

 -  Male healthy subjects and male asthma patients aged 18 to 45 years (inclusive)

 -  Have a body mass index (BMI) between 18 and 30 kg/m2 (inclusive and rounding allowed)
 and weight between 50 and 100 kg (inclusive)

 -  Be able to inhale from the SPIRA nebuliser and I-neb® according to the provided
 instructions

 -  Asthma patients should fulfil the following criteria: Pre-bronchodilator forced
 expiratory volume at 1 second (FEV1) ≥70% of predicted normal value

 -  Asthma diagnosis according to GINA guidelines with a history of episodic wheeze and
 shortness of breath

 Exclusion Criteria:

 -  History of any clinically significant disease or disorder

 -  Any clinically relevant abnormal findings

 -  Current smokers

 -  Asthma patients: Worsening of asthma or respiratory infection within 6 weeks before
 screening

 -  Asthma patients: Use of inhaled, nasal, oral, rectal or parenteral corticosteroids
 within 30 days before first administration of investigational product and during the
 study